Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 14/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 7/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PHF20 | Q9BVI0 | 1/20 | 0.41 |
| ▸ | MORF4L1 | Q9UBU8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685204 | 0.87 | RIPK1 (0.43) | MKNK1MKNK2 | |
| SCHEMBL1685144 | 0.87 | MAPKAPK5 (0.47) | MKNK1MKNK2L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL10134526 | 0.86 | L3MBTL3 (0.44) | MKNK1MKNK2L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3881243 | 0.85 | CDK1 (0.39) | MKNK1MKNK2IKBKBCHUKIKBKG | |
| SCHEMBL1685151 | 0.85 | CCND1 (0.39) | ALDH1A1 | |
| SCHEMBL1685148 | 0.85 | HRH3 (0.38) | — | |
| SCHEMBL1685123 | 0.82 | MAPKAPK2 (0.34) | — | |
| SCHEMBL1685336 | 0.81 | JAK1 (0.35) | — | |
| SCHEMBL10166356 | 0.80 | L3MBTL3 (0.42) | MKNK1MKNK2L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL1792332 | 0.80 | MAPKAPK5 (0.46) | MKNK1MKNK2L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| EP-2099798-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008065199-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MKNK1 113/4885MKNK2 88/4885L3MBTL3 4857/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MKNK1 113/4885MKNK2 88/4885L3MBTL3 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.